# Denali Therapeutics Inc. (DNLI) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Denali Therapeutics Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/DNLI/mda/fy2025/): filed 2026-02-26; accession 0001714899-26-000021 (https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/dnli-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/DNLI/mda/fy2024/): filed 2025-02-27; accession 0001714899-25-000066 (https://www.sec.gov/Archives/edgar/data/1714899/000171489925000066/dnli-20241231.htm)
- [FY 2023 MD&A](/company/DNLI/mda/fy2023/): filed 2024-02-28; accession 0001714899-24-000086 (https://www.sec.gov/Archives/edgar/data/1714899/000171489924000086/dnli-20231231.htm)
- [FY 2022 MD&A](/company/DNLI/mda/fy2022/): filed 2023-02-27; accession 0001714899-23-000049 (https://www.sec.gov/Archives/edgar/data/1714899/000171489923000049/dnli-20221231.htm)
- [FY 2021 MD&A](/company/DNLI/mda/fy2021/): filed 2022-02-28; accession 0001714899-22-000058 (https://www.sec.gov/Archives/edgar/data/1714899/000171489922000058/dnli-20211231.htm)

Back to /company/DNLI/